Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

First Republic (FRC) Q4 Earnings Beat Estimates, Costs Rise

Published 01/13/2020, 09:55 PM
Updated 07/09/2023, 06:31 AM

Driven by top-line strength, First Republic Bank’s (NYSE:FRC) delivered a positive earnings surprise of 10.3% in fourth-quarter 2019. Earnings per share of $1.39 surpassed the Zacks Consensus Estimate of $1.26. Also, the bottom line jumped 7.8% from the year-ago quarter.

Results were supported by increase in net interest income (NII) and non-interest income. Moreover, the company’s balance sheet position remained strong in the quarter. Also, decline in provisions came as a positive factor. However, expenses witnessed a rise.

Net income available to common shareholders grew 9.5% year over year to $235.6 million.

Revenues Increase, Expenses Escalate

Total revenues were $877.5 million, up 8.2% year over year. Also, the figure surpassed the Zacks Consensus Estimate of $849.8 million.

NII jumped 7.9% year over year to $720.1 million, primarily supported by growth in average earning assets. Net interest margin came in at 2.73%, down from 2.98%.

Non-interest income was $157.3 million, up 9.6% year over year. The rise was backed by increase in almost all fee components, except loan servicing fees.

Non-interest expenses for the reported quarter were up 12.1% year over year to $558.8 million. An increase in salaries and benefits, occupancy and information systems expenses from the continued investments in the expansion of the franchises led to the rise.

The efficiency ratio was 63.7% compared with 61.5% recorded in the prior-year quarter. It should be noted that rise in the efficiency ratio indicates lower profitability.

Healthy Balance Sheet

As of Dec 31, 2019, net loans climbed 5.2% sequentially to $90.3 billion while total deposits were up 5.1% to $90.1 billion. Loan originations were $11.2 billion, up 2.4% sequentially.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

First Republic’s total wealth management assets were $151 billion as of Dec 31, 2019, indicating 7.7% sequential rise. This increase resulted from net new assets from existing and new clients, and market appreciation.

Notably, wealth management assets included investment management assets, brokerage assets, money market mutual funds, and trust and custody assets.

Credit Quality: A Mixed Bag

On a year-over-year basis, total non-performing assets increased significantly to $143.2 million. Non-performing assets to total assets ratio was 0.12%, up from 0.05% in the year-ago quarter.

However, provision for loan losses decreased 62% to $9.6 million.

Capital Position

As of Dec 31, 2019, the company’s Tier 1 leverage ratio was 8.39%, indicating fall of 29 basis points from the prior-year quarter. Tier 1 capital to risk-weighted assets was 11.21%, down from 11.7%. Common equity Tier 1 capital to risk-weighted assets ratio was 9.86% compared with 10.38% a year ago.

Tangible book value per share increased 11% to $50.24.

Our Viewpoint

While First Republic has been able to sustain its organic growth momentum, reflected by higher loans and deposits, escalating costs owing to investments in digital initiatives might hurt its bottom line in the near term. Moreover, decline in net interest margin owing to lower interest rates is a concern as it is likely to hurt interest income growth to some extent.

First Republic Bank Price, Consensus and EPS Surprise

First Republic currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Among other mega banks, Bank of America Corporation (NYSE:BAC) and U.S. Bancorp (NYSE:USB) are scheduled to report their quarterly numbers on Jan 15, while Morgan Stanley (NYSE:MS) will report on Jan 16.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>



Bank of America Corporation (BAC): Free Stock Analysis Report

U.S. Bancorp (USB): Free Stock Analysis Report

First Republic Bank (FRC): Free Stock Analysis Report

Morgan Stanley (MS): Free Stock Analysis Report

Original post

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.